News & Updates

Treatment with retatrutide, the novel agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, leads to marked reductions in body weight in individuals with obesity, as shown in the results of a phase II trial.

The HEART-FID trial narrowly missed its primary endpoint, showing modest improvement in all-cause mortality, heart failure hospitalizations (hHF), and exercise function with ferric carboxymaltose (FCM) in HFrEF* patients with iron deficiency (ID).

Long-term treatment with golimumab results in relatively low infection rates among patients with rheumatoid arthritis (RA), a study has shown.

Dapagliflozin for individuals with heart failure (HF) demonstrates consistent safety and efficacy across regions worldwide despite geographic differences in patient characteristics, background treatment, and event rates, reports a recent study.